scholarly journals Role of brain monoamines in the fatal hyperthermia induced by pethidine or imipramine in rabbits pretreated with a monoamine oxidase inhibitor

1973 ◽  
Vol 48 (1) ◽  
pp. 12-18 ◽  
Author(s):  
S. N. C. GONG ◽  
K. J. ROGERS
1995 ◽  
Vol 22 (s1) ◽  
pp. S86-S87 ◽  
Author(s):  
N. Hamaue ◽  
T. Endo ◽  
M. Hirafuji ◽  
N. Yamazaki ◽  
H. Togashi ◽  
...  

1967 ◽  
Vol 113 (505) ◽  
pp. 1407-1411 ◽  
Author(s):  
David Murray Shaw ◽  
Francis E. Camps ◽  
Eric G. Eccleston

There is growing evidence of a connection between the metabolism of monoamines and severe depressive illness, but the exact role of these substances in affective disorders has yet to be defined. We know that reserpine depletes the brain of monoamines and that a proportion of patients treated with this compound develop a depressive illness. Conversely a number of compounds which raise the levels of amines in the brain by blocking the enzyme monoamine oxidase have been used in antidepressant therapy. The knowledge that loss of amines may be associated with depression, and that their replenishment in the brain may induce recovery, immediately leads to the question as to which of the biogenic amines is responsible for the affective changes. Pollin, Cardon and Kety (1961) observed the effect of giving various amino acids together with a monoamine oxidase inhibitor (M.A.O.I.) to patients suffering from chronic schizophrenia. They found that only tryptophan, the precursor of the monoamine 5-hydroxytryptamine (5HT), produced an elevation of mood. On the basis of their results, Coppen, Shaw and Farrell (1963) treated a number of patients suffering from severe depressive illness with M.A.O.I. and half of this group also received an oral dose of a suspension of D L-tryptophan (214 mg./kg. body weight) for one week. The patients taking tryptophan and M.A.O.I. recovered more rapidly than those receiving M.A.O.I. alone both while they were on tryptophan and also subsequently. One explanation for these findings was that the combination of M.A.O.I. and tryptophan increased the amount of amines derived from tryptophan in the brain, and that it was this which was responsible for the therapeutic effect. If this were so, then there were several possibilities. The first was that the level of 5HT in the brain was low in depression and the combination of amine precursor and enzyme inhibitor brought it back to normal. Alternatively it may be that recovery occurred as a result of the presence of abnormally large quantities of 5HT in the central nervous system or even following the production of tryptamine, another amine derived from tryptophan.


1972 ◽  
Vol 54 (2) ◽  
pp. 269-275 ◽  
Author(s):  
A. P. LABHSETWAR

SUMMARY The effect of a monoamine oxidase inhibitor (MAOI) (mebanazine) given alone or in combination with 5-hydroxy-dl-tryptophan (5-HTP) or dihydroxyphenylalanine (l-DOPA) on spontaneous ovulation was tested in 4-day cyclic rats. Injections of the MAOI or 5-HTP alone, which cause a selective rise in the hypothalamic serotonin level, blocked spontaneous ovulation in 32% and 0% of rats, respectively, and in 73% of rats when given together. By contrast, a combination of MAOI and l-DOPA, which causes a selective rise in the hypothalamic catecholamines, did not block ovulation. A single injection of α-methyl-p-tyrosine, but not of α-methyl-m-tyrosine, blocked ovulation in 100% of rats. These results provide experimental support for the existence of a serotoninergic component in the control of ovulation.


1989 ◽  
Vol 4 (3) ◽  
pp. 175-181
Author(s):  
J.F. Lipinski ◽  
R.C. Alexander

SummaryThe authors have reviewed 13 published studies on methionine administration, usually in combination with a monoamine oxidase inhibitor (MAOI), to chronically psychotic patients, using modern (DSM-III) diagnostic criteria. Four of these studies contained sufficient descriptive data to allow reappraisal of the effects. The results of the review suggest that a proportion of the patients experienced the induction of a manic episode/antidepressant effects rather than the reported worsening of schizophrenia while treated with a methionine-MAOI combination. It is suggested that these observations are consistent with recent findings that S-adenosyl-L-methionine (SAMe) has antidepressant and mania-inducing effects.


2010 ◽  
Vol 3 (4) ◽  
pp. 213-215
Author(s):  
Junji Takeshita ◽  
Deborah Goebert ◽  
John Huh ◽  
Brett Lu ◽  
Diane Thompson ◽  
...  

2000 ◽  
Vol 52 (4) ◽  
pp. 451-459 ◽  
Author(s):  
B. D. SLOLEY ◽  
L. J. URICHUK ◽  
P. MORLEY ◽  
J. DURKIN ◽  
J. J. SHAN ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document